Comparison of clinical and biologic features in R and LR CLL patients
| . | R (n = 53)a . | LR (n = 53)a . | P . |
|---|---|---|---|
| Median age, y (range) | 63 (35-82) | 64 (32-84) | NS |
| Female, no. (%) | 21 (40) | 20 (38) | NS |
| Binet stage, no. (%) | |||
| A | 44 (83) | 45 (85) | NS |
| B | 7 (13) | 5 (9) | NS |
| C | 2 (4) | 3 (6) | NS |
| Lymphocytes, no./μLb | 14 200 ± 2900 | 15 700 ± 2100c | NS |
| Lymphocytes, %b | 64.5 ± 2c | 66.4 ± 2.3d | NS |
| Hb, g/dLb | 14.2 ± 0.2d | 13.6 ± 0.3 | NS |
| Plts, no./μLb | 202 000 ± 8000d | 200 000 ± 9000 | NS |
| LDH, U/mLb | 342 ± 10e | 373 ± 20f | NS |
| β2M, g/dLb | 2.1 ± 0.1g | 2.2 ± 0.3h | NS |
| % B CLL cloneg | 73 ± 3d | 72 ± 3i | NS |
| CD38+, no. (%)j | 18 (34) | 19 (37)c | NS |
| ZAP70+, no. (%)k | 14 (26) | 13 (25)e | NS |
| K-light chain, no. (%) | 26 (51)e | 31 (63)i | NS |
| del(11) and/or del(17), no. (%) | 8 (15) | 12 (25)l | NS |
| IGHV unmutated, no. (%) | 10 (20)m | 24 (51)n | .003 |
| . | R (n = 53)a . | LR (n = 53)a . | P . |
|---|---|---|---|
| Median age, y (range) | 63 (35-82) | 64 (32-84) | NS |
| Female, no. (%) | 21 (40) | 20 (38) | NS |
| Binet stage, no. (%) | |||
| A | 44 (83) | 45 (85) | NS |
| B | 7 (13) | 5 (9) | NS |
| C | 2 (4) | 3 (6) | NS |
| Lymphocytes, no./μLb | 14 200 ± 2900 | 15 700 ± 2100c | NS |
| Lymphocytes, %b | 64.5 ± 2c | 66.4 ± 2.3d | NS |
| Hb, g/dLb | 14.2 ± 0.2d | 13.6 ± 0.3 | NS |
| Plts, no./μLb | 202 000 ± 8000d | 200 000 ± 9000 | NS |
| LDH, U/mLb | 342 ± 10e | 373 ± 20f | NS |
| β2M, g/dLb | 2.1 ± 0.1g | 2.2 ± 0.3h | NS |
| % B CLL cloneg | 73 ± 3d | 72 ± 3i | NS |
| CD38+, no. (%)j | 18 (34) | 19 (37)c | NS |
| ZAP70+, no. (%)k | 14 (26) | 13 (25)e | NS |
| K-light chain, no. (%) | 26 (51)e | 31 (63)i | NS |
| del(11) and/or del(17), no. (%) | 8 (15) | 12 (25)l | NS |
| IGHV unmutated, no. (%) | 10 (20)m | 24 (51)n | .003 |
CLL indicates chronic lymphocytic leukemia; IGHV, immunoglobulin heavy chain variable; LDH, lactate dehydrogenase; LR, low responder; NS, nonsignificant; and R, responder.
All cases were evaluable for each of the variables, if not otherwise specified.
Data expressed as mean ± SEM.
Data were available in 52 patients.
Data were available in 51 patients.
Data were available in 47 patients.
Data were available in 46 patients.
Data were available in 27 patients.
Data were available in 26 patients.
Data were available in 49 patients.
CD38 expression was considered positive when > 30%.
ZAP70 expression was considered positive when > 20%.
Data were available in 48 patients.
Data were available in 50 patients.
Data were available in 47 patients.